Synergys Awarded NCI Grant to Develop SYN001 for Triple-negative Breast Cancer

Synergys Awarded NCI Grant to Develop SYN001 for Triple-negative Breast Cancer
The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), awarded Synergys Biotherapeutics a grant to support the development of its antibody fusion molecule SYN001 for the treatment of triple negative breast cancer (TNBC). According to the NIH website, the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grant programs "are one of the largest sources of early-stage capital for technology commercialization in the United States." The programs are investing more than $980 million in fiscal year 2017 in U.S.-owned companies developing therapies and technologies that reflect the mission of the NIH: saving lives and improving health. Synergis was awarded a Phase 1 grant under the SBIR program. Because triple-negative breast cancers are highly proliferative, they require a very efficient network of blood vessels that transport oxygen and nutrients to tumor cells. Researchers have believed for some time that targeting the formation of new blood vessels, either alone or with other treatments, is a viable approach for the treatment of TNBC. But in addition to the development of new blood vessels from pre-existing ones (angiogenesis), recent evidence suggests that the tumor vasculature may also be assembled by tumor cells themselves, a process called vasculogenic mimicry (VM). Current anti-angiogenic therapies only target "true" blood vessels, and are less effective in cancer with a high degree of VM. There are currently no therapies that target both angiogenesis and VM. Synerg
Subscribe or to access all post and page content.

One comment

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.